Bone Loss in Lymphoma Patients Prior to Receiving Front-line Therapy

被引：2
|
作者：
Westin, Jason R. [1 ]
Thompson, Michael A. [2 ]
Cataldo, Vince D. [3 ]
Toth, Bela B. [4 ]
Sanjorjo, Perpetua [5 ]
Bourgeois, Scott [5 ]
Jimenez, Camilo [6 ]
Murphy, William A. [7 ]
Fanale, Michelle [5 ]
Fayad, Luis [5 ]
Fowler, Nathan [5 ]
Kwak, Larry [5 ]
McLaughlin, Peter [5 ]
Neelapu, Sattva [5 ]
Pro, Barbara [5 ]
Rodriguez, Alma [5 ]
Shah, Jatin [5 ]
Hagemeister, Fredrick B. [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Waukesha Mem Hosp, ProHlth Care Canc Ctr, Waukesha, WI USA
[3] Louisiana State Univ, New Orleans, LA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Dent Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2010年 / 10卷 / 03期
关键词：
D O I：
10.3816/CLML.2010.n.042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7
引用
收藏
页码：E32 / E32
页数：1
相关论文
共 50 条
  • [41] Could cisplatin as a front-line treatment in childhood non-Hodgkin's lymphoma be a promising therapy?
    Papadopoulou, AL
    Moschovi, M
    Panagopoulou-Cristaki, M
    Anagnostou-Keramida, D
    Van Vliet-Constantinidou, C
    Botsonis, A
    Tsangaris, GT
    Tzortzatou-Stathopoulou, F
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1999, 16 (04) : 341 - 346
  • [42] Outcomes of Front-Line Therapy for Adult T Cell Leukemia/Lymphoma: A Pooled Analysis of Two Institutions
    Sandoval-Sus, Jose
    Tokumori, Franco Castillo
    Dong, Ning
    Boisclair, Stephanie
    Brahim, Amanda
    Walker, Damaal
    Bridgelall, Sanjay
    Zhang, Ling
    Saeed, Hayder
    Sokol, Lubomir
    BLOOD, 2020, 136
  • [43] Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
    Thomas, Colin
    Thapa, Sameep
    McLaughlin, Connor
    Halloran, Molly
    Porcu, Pierluigi
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [44] No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan
    D. Focosi
    L. Macera
    E. Ciabatti
    S. Galimberti
    M. Petrini
    A. M. Carella
    M. Pistello
    L. Ceccherini-Nelli
    F. Maggi
    Infection, 2014, 42 : 1065 - 1066
  • [45] No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan
    Focosi, D.
    Macera, L.
    Ciabatti, E.
    Galimberti, S.
    Petrini, M.
    Carella, A. M.
    Pistello, M.
    Ceccherini-Nelli, L.
    Maggi, F.
    INFECTION, 2014, 42 (06) : 1065 - 1066
  • [46] High-dose therapy and ASCT versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: Long term results
    Carella, A. M.
    Bellei, M.
    Brice, P.
    Gisselbrecht, C.
    Visani, G.
    Colombat, P.
    Fabbiano, F.
    Donelli, A.
    Feugier, P.
    Browett, P.
    Hagberg, H.
    Federico, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 33 - 33
  • [47] Issues of front-line therapy for multiple myeloma - the standard of care
    Rosinol, Laura
    Blade, Joan
    LEUKEMIA & LYMPHOMA, 2014, 55 (09) : 1959 - 1961
  • [48] Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia
    Reagan, John L.
    Castillo, Jorge J.
    FUTURE ONCOLOGY, 2014, 10 (07) : 1147 - 1155
  • [49] Front-line therapy of advanced ovarian cancer: new approaches
    Ledermann, J. A.
    ANNALS OF ONCOLOGY, 2017, 28 : 46 - 50
  • [50] Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer
    Szabados, Bernadett
    Prendergast, Aaron
    Jackson-Spence, Francesca
    Choy, Julia
    Powles, Thomas
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (06): : 943 - 947
12345